Treating heart failure on dialysis. Finally getting some evidence

J Am Coll Cardiol. 2010 Nov 16;56(21):1709-11. doi: 10.1016/j.jacc.2010.03.106.

Authors

Ilke Sipahi¹, James C Fang

Affiliation

¹ Harrington-McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.

PMID: 21070921
DOI: 10.1016/j.jacc.2010.03.106

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin II Type 1 Receptor Blockers / administration & dosage
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Benzimidazoles / administration & dosage
Benzimidazoles / therapeutic use*
Benzoates / administration & dosage
Benzoates / therapeutic use*
Dose-Response Relationship, Drug
Drug Therapy, Combination
Heart Failure / epidemiology
Heart Failure / therapy*
Humans
Italy / epidemiology
Length of Stay
Morbidity / trends
Renal Dialysis / methods*
Telmisartan
Treatment Outcome

Substances

Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Benzimidazoles
Benzoates
Telmisartan